Elex Biotech LLC is developing new drugs targeting factors associated with the internal membrane system controlling the contractile state of cardiac muscle, with the aim of treating Ventricular Arrhythmias. Ventricular Arrhythmias and Heart Failure are the major cause of death in the United States and, as a result, are responsible for a huge financial and emotional burden to the families involved. Treatment options for the termination or suppression of Ventricular Arrhythmia include Implantable Cardioverter Defibrillators (ICD), catheter ablation, or Anti-Arrhythmic Drugs. But the efficacy of anti-arrhythmic drugs for the treatment of ventricular tachycardia remains suboptimal, and in some cases results in an increased risk of mortality. Existing medications tend to be only mildly effective and relatively non-specific. In order to meet the urgent need for effective therapeutics, Elex has developed new, more potent medications to treat ventricular arrhythmias. The company has ties to Portland State University.
